BV Improves Outcomes in HL

Results from the AETHERA Trial, a phase III, randomised, double-blind, placebo controlled, multicentre study, showed that the addition of brentuximab vedotin (BV) following autologous stem cell transplant (ASCT) resulted in longer progression-free survival (PFS) compared with best supportive care in those with relapsed or refractory Hodgkin lymphoma (HL).

Findings were presented at the 2014 American Society of Hematology annual meeting. Patients (n = 327) were randomised to receive either BV or BSC. At a median follow-up of two years, those receiving BV had a 20% improvement with no disease progression and 88% of patients who received BV were still alive.

Read more here.


Global Database

Information by country, region and/or subtype on treatments, clinical trials and incidence/mortality rates.

Resource Library

Over 2,000 pieces of information on lymphoma diagnosis, treatment, research, support and lifestyle.

logo europe


Have you ever attended a meeting with a lymphoma support group?




The information on this website is for general use only. Please consult your physician if you think you may have lymphoma or
require more detailed information on the best course of treatment for you.

Our website does not host any form of advertisement. Last updated: 03/27/18. Copyright © 2018 Lymphoma Coalition. All rights reserved.